Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 4/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15531882 | 0.79 | NAMPT (0.59) | NAMPTSMN1; SMN2NPC1ALDH1A1CYP19A1 | |
| SCHEMBL15533702 | 0.75 | NAMPT (0.63) | NAMPTPOLB | |
| SCHEMBL4257980 | 0.74 | FPR3 (0.45) | ALDH1A1KDM4ELMNAPOLBHTT | |
| SCHEMBL4256180 | 0.73 | KDM4E (0.50) | SMN1; SMN2NPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL16227562 | 0.73 | NAMPT (0.64) | NAMPTSMN1; SMN2NPC1ALDH1A1CYP19A1 | |
| SCHEMBL4252915 | 0.72 | HCAR2 (0.46) | SMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL4249606 | 0.72 | HCAR2 (0.41) | ALDH1A1KDM4ELMNA | |
| SCHEMBL7807304 | 0.71 | QPCT (0.54) | QPCTNAMPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL13472388 | 0.71 | TP53 (0.46) | SMN1; SMN2NPC1ALDH1A1TBXAS1LMNA | |
| SCHEMBL6398857 | 0.70 | L3MBTL1 (0.68) | QPCTNAMPTSMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | claimed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | claimed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | QPCT 1468/4885NAMPT 2929/4885SMN1; SMN2 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.